Nachrichten zur Protagonist Therapeutics Aktie

The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib…

…

MIMRYLO ist als erstes und einziges Hepcidin-Mimetikum für Erwachsene mit Polycythaemia vera zugelassen. Die FDA-Zulassung löst 275 Mio. USD…

Protagonist Therapeutics setzt bei peptidbasierten Therapeutika auf Umsatzbeteiligungen durch strategische Partnerschaften mit führenden Pharmakonzernen. Die FDA-Zulassung von ICOTYDE im…

Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest…

The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but…

Image source: The Motley Fool.DATEWednesday, March 10, 2021 at 10:12 p.m. ETCALL PARTICIPANTSChief Executive Officer — Dinesh PatelChief Medical Officer…

Geschäftstreiber: Protagonist Therapeutics (PTGS) hat sich auf die Entwicklung peptidbasierter Therapeutika spezialisiert, wobei man sich auf neue Ansätze zur Behandlung…

…

These are the stocks posting the largest moves midday.…

Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people…

Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports…

Protagonist Therapeutics stock surges after J&J acquisition talks report…

Key PointsGAAP loss per share of $0.55 in Q2 2025 beat analyst estimates by $1.13.GAAP revenue of $5.5 million in…

…

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 62% and 149.90%, respectively, for the quarter ended March 2025. Do…

The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this…

Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…

Protagonist Therapeutics ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entdeckung und Entwicklung von peptidbasierten Therapeutika konzentriert.…

Truist raises Protagonist Therapeutics target to $76…

Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for…

Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN),…